Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients.
Pedro R J AlmeidaAlexandre M PeriardFernanda L TanaRenata E AvilaLarissa B MilhoratoKatlen M M AlcantaraCarolina B ResendeAngela V SerufoFelipe Rocha da Silva SantosDanielle C TeixeiraCelso M Queiroz-JuniorTalita C M FonsecaBarbara L V SilvaVivian V CostaRenan Pedra de SouzaMauro PerrettiThomas E N JonassenMauro Martins TexeiraPublished in: British journal of pharmacology (2024)
Treatment with AP1189 was associated with less disease caused by beta-coronavirus infection both in mice and in humans. This is the first demonstration of the effects of a pro-resolving molecule in the context of severe infection in humans.
Keyphrases
- sars cov
- study protocol
- placebo controlled
- coronavirus disease
- phase iii
- anti inflammatory
- phase ii
- transcription factor
- double blind
- respiratory syndrome coronavirus
- randomized controlled trial
- stem cells
- drug induced
- squamous cell carcinoma
- cell therapy
- metabolic syndrome
- adipose tissue
- radiation therapy
- type diabetes
- skeletal muscle
- mesenchymal stem cells
- bone marrow
- insulin resistance
- rectal cancer